Form 4 for OGN Organon & Co.
Accepted 2026-04-02 16:18:37 ET · period of report 2026-03-31 · accession 0001628280-26-023188 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2026-04-02 16:18 | 2026-03-31 | OGN | Arjona Ferreira Juan Camilo | CMO, Head of R, D | M - OptEx | $0.00 | +13.4K | 34.9K | +63% | $0 |
| D | 2026-04-02 16:18 | 2026-03-31 | OGN | Arjona Ferreira Juan Camilo | CMO, Head of R, D | F - Tax | $5.70 | -4,820 | 30.0K | -14% | -$27.5K |
| D | 2026-04-02 16:18 | 2026-03-31 | OGN | Arjona Ferreira Juan Camilo | CMO, Head of R, D | A - Grant | $0.00 | +200.3K | 200.3K | New | $0 |
| D | 2026-04-02 16:18 | 2026-03-31 | OGN | Arjona Ferreira Juan Camilo | CMO, Head of R, D | M - OptEx | $0.00 | -13.4K | 26.9K | -33% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2026-03-31 | M | A | 13,431 | $0.00 | 34,867.48 | D | — | — | |
| 2 | Common | Common Stock | 2026-03-31 | F | D | 4,820 | $5.70 | 30,047.48 | D | — | — | (F1) The price is the closing market price of Organon & Co. ("Organon") common stock on Monday, March 30, 2026, as required by the plan under which the Restricted Stock Units ("RSU") were awarded. |
| 3 | Derivative | Restricted Stock Units | 2026-03-31 | A | A | 200,333 | $0.00 | 200,333 | D | — · — to — | 200,333 Common Stock | (F2) On March 31, 2026, the Reporting Person was granted 200,333 RSUs, with each RSU representing a contingent right to receive one share of Organon common stock. These RSUs will vest and become exercisable in three equal installments on March 31, 2027, March 31, 2028, and March 31, 2029. (F2) On March 31, 2026, the Reporting Person was granted 200,333 RSUs, with each RSU representing a contingent right to receive one share of Organon common stock. These RSUs will vest and become exercisable in three equal installments on March 31, 2027, March 31, 2028, and March 31, 2029. (F2) On March 31, 2026, the Reporting Person was granted 200,333 RSUs, with each RSU representing a contingent right to receive one share of Organon common stock. These RSUs will vest and become exercisable in three equal installments on March 31, 2027, March 31, 2028, and March 31, 2029. |
| 4 | Derivative | Restricted Stock Units | 2026-03-31 | M | D | 13,431 | $0.00 | 26,864 | D | — · — to — | 13,431 Common Stock | (F3) Each RSU represents a contingent right to receive one share of Organon common stock. (F4) On March 31, 2025, the Reporting Person was granted 40,295 RSUs. One-third of such RSUs vested on March 31, 2026, with the remaining two-thirds to vest on March 31, 2027 and March 31, 2028. (F4) On March 31, 2025, the Reporting Person was granted 40,295 RSUs. One-third of such RSUs vested on March 31, 2026, with the remaining two-thirds to vest on March 31, 2027 and March 31, 2028. |